nDatalyze Corp (NDAT) AI Stock Analysis

• Market Cap: C$619.91K
• Dividend Yield: N/A
• Average Volume (3M): 9.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.41
• Revenue Growth: -92.67%
• EPS Growth: 20.42%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 41,327,423
• 10 Day Avg. Volume: 16,050
• 30 Day Avg. Volume: 9,616
• PEG Ratio: 0.12
• Price to Book (P/B): 7.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

nDatalyze Corp's overall stock score reflects significant financial struggles with declining revenues and negative cash flows. Technical indicators suggest a bearish trend, while valuation metrics are unattractive due to persistent losses. Although the company has a strong equity position, operational challenges and reliance on external financing remain concerns. The recent corporate events hold potential but are not enough to offset the current financial and market challenges.

nDatalyze Corp Business Overview & Revenue Model

Company Description

nDatalyze Corp. generates technology-based health-related solutions. It is developing a machine-learning based online consumer mental health application and database licensing. The company also engages in the manufacture and sale of essential oil CO2 extraction and alcohol-based equipment. It serves medical cannabis growers. The company was formerly known as MedXtractor Corp. and changed its name to nDatalyze Corp. in October 2021. nDatalyze Corp. was incorporated in 2018 and is headquartered in Calgary, Canada.

How the Company Makes Money

nDatalyze Corp generates revenue primarily through subscription-based access to its YMI platform. Healthcare providers, clinics, and individual users subscribe to the platform for its mental health assessment tools, which utilize advanced data analytics to offer personalized insights and recommendations. The company may also explore partnerships with healthcare organizations and technology firms to expand its market reach and enhance its service offerings. Additionally, nDatalyze may engage in research collaborations or licensing agreements to further monetize its proprietary technologies and data assets.

nDatalyze Corp Financial Statement Overview

Summary

nDatalyze Corp is facing financial difficulties characterized by declining revenues and persistent losses. The company maintains a strong equity position with no debt, which provides some financial stability. However, the negative cash flows and the need for external financing point to underlying operational challenges that need addressing to improve the financial health of the company.

Income Statement

nDatalyze Corp's income statement reveals a challenging financial environment. The company has experienced a significant decline in revenue from 2020 to 2024, with the latest year showing a dramatic drop in total revenue to 96,342. This results in negative EBIT and net income, leading to a negative net profit margin. Gross profit margin remains positive but shrinking. The consistent negative EBITDA margin indicates ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with no debt, resulting in a favorable debt-to-equity ratio of 0. Stockholders' equity is healthy relative to total assets, but there is a declining trend in total assets and equity over the years. The equity ratio remains strong, showing the company is not highly leveraged. This stability in equity is a positive factor amidst declining revenues.

Cash Flow

Cash flow analysis indicates significant challenges, with negative operating and free cash flows persistently over recent years. The free cash flow growth rate is negative, showing deteriorating cash generation capability. However, the company has managed to maintain liquidity through financing activities, boosting cash reserves temporarily.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
47.23K	96.34K	171.22K	424.93K	662.77K	531.17K
	Gross Profit
43.23K	67.39K	44.84K	229.98K	376.73K	316.92K
	EBIT
-965.43K	-455.38K	-1.25M	-1.18M	-687.48K	-45.10K
	EBITDA
-940.74K	-429.24K	-1.23M	-1.17M	-688.51K	-25.69K
	Net Income Common Stockholders
-668.00K	-155.60K	-1.23M	-1.17M	-698.53K	-36.60K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
644.51K	794.10K	742.74K	1.60M	781.39K	594.49K
	Total Assets
751.53K	877.91K	862.01K	1.71M	872.95K	673.84K
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-644.51K	-794.10K	-742.74K	-1.60M	-781.39K	-594.49K
	Total Liabilities
63.60K	38.26K	289.27K	81.42K	71.87K	36.92K
	Stockholders Equity
687.92K	839.65K	572.74K	1.63M	801.08K	636.92K
Cash Flow		Free Cash Flow
-440.32K	-221.64K	-1.03M	-1.14M	18.90K	90.36K
	Operating Cash Flow
-438.77K	-217.46K	-1.02M	-1.13M	20.75K	92.12K
	Investing Cash Flow
-1.55K	-4.17K	-4.39K	-13.85K	-1.84K	-1.75K
	Financing Cash Flow
467.99K	273.00K	175.54K	1.95M	168.00K	360.64K

nDatalyze Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NDAT, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.19 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NDAT.

nDatalyze Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
NDAT	39 Underperform	C$619.91K	―	-60.84%	―	-92.67%	20.42%
CRDL	38 Underperform	C$163.65M	―	-190.61%	―	―	-18.03%
NXO	22 Underperform	C$1.95M	―	17.92%	―	―	83.87%

nDatalyze Corp Corporate Events

nDatalyze Corp. Advances RTO and Prepares New Product Launch

nDatalyze Corp. has announced ongoing progress in its Reverse Takeover with ThriveTech Holdings, with discussions continuing regarding share distribution post-RTO. Additionally, the company is nearing the launch of ‘Sigmund,’ a new product line targeting the EMR, concierge medical, and performance coaching markets, which integrates AI and DNA-based mental condition assessments.

nDatalyze Corp Completes Due Diligence for Reverse Takeover

nDatalyze Corp has completed due diligence for a reverse takeover involving Thrive Tech Holdings, Inc., which now owns Ameresco Holding LLC. The revised letter of intent outlines changes such as replacing the board of directors and officers, spinning out mental health assets to a separate private company owned by existing shareholders, and issuing new common shares. The transaction requires regulatory and shareholder approvals, and there are no plans for share consolidation. Thrive Tech Holdings reported significant revenue and profit, highlighting its focus on internet-based brands.

nDatalyze Corp Addresses Stock Price Decline Amidst Ongoing Initiatives

nDatalyze Corp has addressed the recent decline in its stock price, stating there are no undisclosed changes within the company to account for this fluctuation. With a stable financial position, no debt, and ongoing advancements in technical and commercialization initiatives, the company continues its due diligence on a previously announced RTO, indicating a focus on future growth and industry presence.

nDatalyze Corp Enhances Mental Health Assessment with AI Calibration

nDatalyze Corp announced the AI-based calibration of its CMCP-5 Anxiety assessment algorithm, which, along with a previously announced depression algorithm, is being migrated to Google Cloud. This advancement allows for more accurate and cost-effective assessments without real-time processing, facilitating integration into third-party applications like Electronic Medical Records. This development aims to improve the differentiation between anxiety and depression, addressing a major challenge in mental health diagnosis and treatment, ultimately leading to better patient outcomes.